Best Practices of HCP Clearance in Downstream Processing of mAbs
Merck: Best Practices of HCP Clearance in Downstream Processing of mAbs
In this webinar, you will learn:
- What are Host cell proteins?
- Best practices of HCP removal in downstream processing.
- HCP control in intensified processing
Detailed description:
Host cell proteins (HCPs) are process related impurities in a therapeutic monoclonal antibody (mAb) using cell culture technology. This webniar presents biopharmaceutical industry trends for HCP in bioprocessing and the best practices for HCPs clearance in the downstream unit operations. The webinar will discuss on the current technologies for its removal in the downstream unit operations and also for intensified downstream processing of monoclonal antibody.
An on-demand version of this webinar will be available after the live event using the same link. Register now and access the webinar at your convenience.
Presenter: Mr. Bin Wang (Director of Technical & Scientific Solutions Group, China)
Mr. Bin Wang is the Director of Technical & Scientific Solutions Group in Merck China, wherein he leads a strong globally networked teams including MSAT, Technical Operation, Tech Service and Field Service. This group is the technical function of Merck Bioprocessing who provides comprehensive solution covering process development and scaling-up, FCD & process engineering, technic inquiry & consultation, HW qualification & implementation. Before this position, he used to lead Asia Biomanufacturing team to support PD, scaling up and implementation activities for Asia biopharmaceutical companies. Between 2016 to 2017, Bin Wang worked in EMD Millipore USA MSAT team to provide technical solution for biopharmaceutical companies in North America.
Presenter: Takao Ito (Principal Consultant)
Takao Ito serves as a principal consultant at Global BioPharm Center of Excellence focused on biopharmaceutical processing. He has over 20 years experiences in the area of bioprocess engineering, working across multiple technologies within bioprocess development, scale-up, and GMP manufacturing. He currently helps the intensified bioprocess grow and evolve innovative technologies for the upstream/downstream applications.
Presenter: Subhasis Banerjee Ph.D. (Principal Process Consultant, APAC)
Subhasis supports technical consultation on Process Development , Scaleup and troubleshooting for downstream processing for the APAC region. Subhasis has a Ph.D. in Biochemistry with a post-doctoral experience from The Ohio State University, Columbus, Ohio, USA. Dr. Banerjee has several publications in international peer reviewed journals and presentations in several national and International Conferences.
Moderator: Benjamin Park (Senior Technical Application Expert)
Benjamin joined Merck in February 2019 as a Technology Manager in the Process Solution division with a focus on Virus Filtration Process and Sterile Sampling System. Before joining Merck, Benjamin worked as a researcher in GC Pharma R&D Center, exploring the field of downstream process, particularly to protein purification process development. He holds a patent for ‘Method for Purifying A Sulfatase Protein’ in 2017. His educational background includes a M.S. in Biological Sciences from Purdue University (US).